

Amendments to the Specification:

The paragraph starting at page 25, line 25 has been amended as follows:

The binding agent may bind to the protein core or the HS chains of the GPC5 molecule, but in preferred embodiments binds to the protein core, preferably to the hydrophilic regions of the core, e.g. to part or all of the sequence CKSYTQRVVGNGIKAQ (SEQ ID NO: 1)

Table 1 on page 39-40 of the specification has been amended as follows:

Primers and Probes for Genomic Quantification of GPC5		
GPC5 Forward	5'- CCCACCCAAATCTCATCTAGAATT-3' (SEQ ID NO: 5)	300 nM
GPC5 Probe - FAM Labelled	5' - CCGGGTTCCTCCCTTTGCACATG-3' (SEQ ID NO: 6)	100 nM
GPC5 Reverse	5' - ACGCATTGCCCAGTTGTTAGA (SEQ ID NO: 7)	300 nM
GJB2 Forward	5' - TGGTTGCATTTAAGGTCAGAATCTT - 3' (SEQ ID NO: 8)	50 nM
GJB2 Probe - Vic Labelled	5' - CTAGCGACTGAGCCTTGACAGCTGAGC - 3' (SEQ ID NO: 9)	100 nM
GJB2 Reverse	5' - GCAGAGGCACGTTTCAGGAA-3' (SEQ ID NO: 10)	300 nM
Primers and Probes for Expression Quantification of GPC5		
GPC5 Forward	5'- GGGCTGCCGGATTCG - 3' (SEQ ID NO: 11)	300 nM
CPC5 Probe - FAM Labelled	5' - CGCGGCAGGACCTGATCTTCA -3' (SEQ ID NO: 12)	300 nM
GPC5 Reverse	5' - CTGGTGCAACATGTAGGCTTTT -3' (SEQ ID NO: 13)	300 nM

GAPDH PDAR	Applied Biosystems Part No. 4310884E	1X
Primers and Probes for Genomic Quantification of GPC6		
GPC6 Forward	5'- TGACCAGCTCAAGCCATTG -3' (SEQ ID NO: 14)	50 nM
GPC6 Probe - FAM Labelled	5' - AGACGTGCCCCGGAACTGAAGATTC (SEQ ID NO: 15)	100 nM
GPC6 Reverse	5' - TGAAGGCGCGGGTAACC -3' (SEQ ID NO: 16)	300 nM
Primers and Probes for Expression Quantification of GPC6		
GPC6 Forward	5' - AACGAGGAGGAATGCTGGAA -3' (SEQ ID NO: 17)	300 nM
GPC6 Probe - FAM Labelled	5' = CACAGCAAAGCCAGATACTTGCCTGAGATC -3' (SEQ ID NO: 18)	100 nM
GP6 Reverse	5' - CTGGTTGGTGAGCCCATCAT - 3' (SEQ ID NO: 19)	50 nM
Primers for amplification of GPC5 sequence including restriction sites and kozak sequence		
GPC5 Forward	5' TATAAGCTTCCACCATGGACGCACAGACCTGGCCCG-3' (SEQ ID NO: 20)	300 nM
GPC5 Reverse	5' - CGCGTCGACTTACCAAATCCCGGGAAGTA - 3' (SEQ ID NO: 21)	300 nM

The paragraph starting at page 40, line 3 of the specification has been amended as follows:

Antisense Oligonucleotides (ASOS) Targeted to GPC5 and WT1. 20 mer, 2'-O-methoxyethyl (2'-MOE) chimeric oligonucleotides consisting of a central window of eight 2'-deoxy unmodified sugar residues with flanking 2'-MOE regions and a fully thioated backbone were synthesized by Isis Pharmaceuticals Inc., as described previously (Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., and Bennett, C. F. (1997) J Biol Chem 272, 11994-12000). Twenty antisense oligonucleotides targeting predicted accessible GPC5 mRNA sequences over the full length mRNA product were provided and screened for activity in K562 cells. ISIS 15770, sequence 5'-ATGCATTCTGCCCCCAAGGA-3' (SEQ ID NO: 22), a 5-10-5 gapmer targeting murine *c-raf* kinase was used as a control in this

screen. The two active compounds identified were ISIS 276107 sequence 540 - CAGCCCCCTGACAGCTCCCA-3' (SEQ ID NO: 23), and ISIS 276119 sequence 5' - CCATCTGCAGCAGCTAATTC-3' (SEQ ID NO: 24). Also used as a control was ISIS 276124, sequence 5'-TGGATTTGCTTTACATCACT-3' (SEQ ID NO: 25)

The paragraph starting at page 40, line 21 has been amended as follows:

The previously identified WT1 ASOs were ISIS 16609, sequence 5' - GCCCTTCTGTCCATTTCCT-3' (SEQ ID NO: 26), targeting WT1 exon 5 (ASWT1exon 5) and ISIS 16601, sequence 5'-CACATACACATGCCCTGGCC-3' (SEQ ID NO: 27), targeting the 3'-UTR region of *WT1* (ASWT13'UTR). The control ASO was ISIS 105730, sequence 5'-CCATCGACCTGCACCGATCA-3' (SEQ ID NO: 28), a scrambled sequence of *ASWT13'UTR*, (*ASWT1*scram).